Skip to content
MedsAcross

Medicine

Yimmugo 5 g/50 mL injection

Human immunoglobulin g · Intravenous · Biotest
Available on requestPrescription onlyUS FDA Cold chain

Yimmugo 5 g/50 mL injection is a prescription medicine containing Human immunoglobulin g for intravenous use, marketed by Biotest, with its source record on the US FDA register. It is available on request for export supply from India to licensed hospitals, importers and physicians. It ships in a temperature-controlled cold chain.

Availability

Available on request

Export supply from India to licensed buyers

Typical lead time

On request

Counted from payment and complete documents

Shipping

Cold chain

Refrigerate between 2°C to 8°C (36°F to 46°F). Once the product has been taken…

Key facts

Active ingredient (INN)
Human immunoglobulin g
Brand
Yimmugo
Strength
5 g/50 mL
Dosage form
Injection
Route
Intravenous
Packs
1 vial of 50 mL
Marketing authorisation holder
Biotest
Manufacturers
BiotestKedrion Biopharma
Origin register
US FDA, United States
Storage
Refrigerate between 2°C to 8°C (36°F to 46°F). Once the product has been taken out of the refrigerator, it must not be returned to the refrigerator. Within the expiration date, the product may be stored at room temperature (more than 8°C and up to 25°C/ more than 46°F and up to 77°F) for a single period not exceeding 12 months.
Cold chain
Yes, shipped temperature controlled
Prescription status
Prescription only
Controlled substance
Not recorded as controlled
ATC code
J06BA02 Human immunoglobulin g
HS code (indicative)
3002.12Indicative only. Your customs broker confirms the final tariff code.
Marketing category
marketed
Marketed since
1 March 2025
Identifiers
RxCUI 2706386, 2706393, 2706395 +3DailyMed set ID 50fc5ffc-49aa-51f2-e063-6294a90a59cf, 77aaac18-f2af-46c4-8f65-b15be1cec3c2NDC 70573-605, 83372-605Application BLA125810

Record updated 12 November 2026

Documents available

Documents that can be provided with this medicine. Your regulator may ask for more, and the quote lists the full set.

No document list is recorded for this medicine yet. Tell us which documents your regulator needs (for example a CoA, COPP or GMP certificate) when you request a quote.

Packs

PackCodeLabelerMarketed since
1 vial, glass in 1 carton / 50 mL in 1 vial, glass83372-605-01Biotest1 March 2025
1 vial, glass in 1 carton / 50 mL in 1 vial, glass70573-605-01Kedrion Biopharma1 July 2025

Status by register

Where this medicine is registered, from the source record and the regulator data we hold. Ask us about a country that is not listed.

RegisterStatusSource
US FDAListed, marketedSource record for this pageChecked 12 November 2026
EU (EMA)Not recorded—
India (CDSCO)Not yet confirmed against CDSCO approval lists—
United StatesRegisteredUS FDA (NDC directory, openFDA)Checked 12 November 2026

Import route

Pick the destination country to see the legal import route, who applies and typical timelines, from our import guide for that country.

Import guides are available for 25 countries. Pick one to see its route summary.

BrazilColombiaEgyptEthiopiaGhanaIraqKazakhstanKenyaAll import guides

Alternatives

Other makers and brands of Human immunoglobulin g 5 g/50 mL injection.

Compare all 8

Other strengths and forms of Human immunoglobulin g

Clinical summary

Human immunoglobulin g is a human immunoglobulin G indicated for the treatment of adults and pediatric patients 2 years of age and older with primary humoral immunodeficiency (PI). MedsAcross supplies Human immunoglobulin g for export from India to licensed hospitals, importers and physicians acting for named patients, with the documents each country requires.

Information from the US FDA prescribing information, retrieved 12 November 2026. Not yet medically reviewed.How we review

Read about Human immunoglobulin g

For healthcare professionals and buyers. This is not medical advice. Treatment decisions belong to the prescriber.

Data sources

Need Yimmugo 5 g/50 mL injection for your hospital or patient?

Send one request with the destination country and quantity. We confirm availability, lead time and the documents your regulator needs.